Ophthalmic drug delivery systems for the treatment of retinal diseases: Basic research to clinical applications

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 11, 2010, Pages 5403-5420

  Edelhauser, Henry F ^a   Rowe Rendleman, Cheryl L ^b   Robinson, Michael R ^c   Dawson, Daniel G ^a   Chader, Gerald J ^d   Grossniklaus, Hans E ^a   Rittenhouse, Kay D ^e   Wilson, Clive G ^f   Weber, David A ^g   Kuppermann, Baruch D ^h   Csaky, Karl G ⁱ   Olsen, Timothy W ^a   Kompella, Uday B ^j   Holers, V Michael ^k   Hageman, Gregory S ^l,m   Gilger, Brian C ⁿ   Campochiaro, Peter A ^o   Whitcup, Scott M ^c   Wong, Wai T ^p  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Omar Consulting Group   (United States)

^c ALLERGAN INC   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e PFIZER INC   (United States)

^f UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^g Macu Sight   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF COLORADO   (United States)

^k Taligen Therapeutics   (United States)

^l UNIVERSITY OF IOWA   (United States)

^m UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

ⁿ NORTH CAROLINA STATE UNIVERSITY   (United States)

^o JOHNS HOPKINS UNIVERSITY   (United States)

^p NATIONAL EYE INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BEVACIZUMAB; CARBOPLATIN; CORTICOSTEROID; DEXAMETHASONE; DOXYCYCLINE; FLUOCINOLONE ACETONIDE; GANCICLOVIR; I VATION; ILUVIEN; IMMUNOSUPPRESSIVE AGENT; MINOCYCLINE; RANIBIZUMAB; RAPAMYCIN; RETINOL; STEROID; TOPOTECAN; TRIAMCINOLONE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VERISOME; VOCLOSPORIN;

ARTICLE; BLOOD RETINA BARRIER; BRUCH MEMBRANE; CATARACT; CYTOMEGALOVIRUS RETINITIS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG SAFETY; DRY EYE; ENDOPHTHALMITIS; ENUCLEATION; GENE THERAPY; GLAUCOMA; HUMAN; IONTOPHORESIS; LASER COAGULATION; PATHOGENESIS; PERMEABILITY BARRIER; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINITIS PIGMENTOSA; RETINOBLASTOMA; SUSTAINED DRUG RELEASE; UVEITIS; VITREOUS BODY DETACHMENT;

BIOMEDICAL RESEARCH; DRUG DELIVERY SYSTEMS; HUMANS; OPHTHALMIC SOLUTIONS; PHARMACEUTICAL PREPARATIONS; RETINAL DISEASES;

EID: 79955022978     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-5392     Document Type: Article

References (78)

1. Edelhauser HF, Boatright JH, Nickerson JM, and the Third ARVO/ Pfizer Research Institute Working Group. Drug delivery to posterior intraocular tissues: third annual ARVO/Pfizer ophthalmics research institute conference. Invest Ophthalmol Vis Sci. 2008;49: 4712-4720.
2. Hughes PM, Olejnik O, Chang-Lin JE, Wilson CG. Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev. 2005;57:2010-2032.
3. Business Insights: The Ophthalmic pharmaceutical market outlook to 2014: competitive landscape, pipeline analysis, growth opportunities and market forecasts. http://www.Pharmalicensing.com. Accessed January 2, 2010.
4. Yuker HE. Perceptions of severely and multiply diasabled persons. J Multiple Handicapped Person. 1988;1:5-15.
5. Geroski DH, Edelhauser HF. Drug delivery for posterior segment diseases. Invest Ophthalmol Vis Sci. 2000;41:961-964.
6. Ghate D, Edelahauser HF. Ocular drug delivery. Expert Opin Drug Deliv. 2006;3:275-287.
7. Kim SH, Lutz RJ, Wang NS, Robinson MR. Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res. 2007;39:244-254.
8. Frederici TJ. Intravitreal injections: AAO's Focal Points. Clinical Modules for Ophthalmologists. 2009;27(8, module 2):1-12.
9. Jager RD, Aiello LP, Patel SC, Cunningham ET. Risks of intravitreous injection: a comprehensive review. Retina. 2004;24:676-698.
10. Durairaj C, Shah JC, Senapati S, Kompella UB. Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR). Pharm Res. 2009;26:1236-1260.
11. Le Goff MM, Bishop PN. Adult vitreous structure and postnatal changes. Eye. 2008;22:1214-1222.
12. Bishop PN. Structural macromolecules and supramolecular organisation of the vitreous gel. Prog Retin Eye Res. 2000;19:323-344.
13. Worst JG, Los LI. Comparative anatomy of the vitreous body in rhesus monkeys and man. Doc Ophthalmol. 1999;82:169-178.
14. Fowlks WL. Meridional flow from the corona ciliaris through the pararetinal zone of the rabbit vitreous. Invest Ophthalmol Vis Sci. 1963;2:63-71.
15. Smelser GK, Ishikawa T, Pei YF. Electron microscopic studies of intra-retinal spaces: diffusion of particulate materials. In: Rohen JW, ed. Eye Structure, II. Stuttgart, Germany: Schattauer-Verlag; 1965.
16. Törnquist P, Alm A, Bill A. Permeability of ocular vessels and transport across the blood-retinal-barrier. Eye. 1990;4:303-309.
17. Mannermaa E, Vellonen KS, Urtti A. Drug transport in corneal epithelium and blood retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev. 2006;58:1136-1163.
18. Gaudana R, Jwala J, Boddu SHS, Mitra AK. Recent perspectives in ocular drug delivery. Pharm Res. 2009;26:1197-1216.
19. Winkler BS. Glycolytic and oxidative metabolism in relation to retinal function. J Gen Physiol. 1981;77:667-692.
20. Lee SS, Robinson MR. Novel drug delivery systems for retinal diseases. Ophthalmic Res. 2009;41:124-135.
21. MacDonald IM, Sauvé Y, Sieving PA. Preventing blindness in retinal disease: ciliary neurotrophic factor intraocular implants. Can J Ophthalmol. 2007;42:399-402.
22. Sieving PA, Caruso RC, Tao W, et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci. 2006;103:3896-3901.
23. US National Institutes of Health. ClinicalTrials.org. NCT00447954 CgI. A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration. Phase II study. 2009. http://clinicaltrials.gov/ct2/show/NCT00447954. Accessed December 24, 2009.
24. Raghava S, Hammond M, Kompella UB. Periocular routes for retinal drug delivery. Expert Opin Drug Deliv. 2004;1:99-114.
25. Ghate D, Brooks W, McCarey BE, Edelhauser HF. Pharmacokinetics of intraocular drug delivery by periocular injections using ocular fluorophotometry. Invest Ophthalmol Vis Sci. 2007;48:2230-2237.
26. Robinson MR, Lee S, Kim H, et al. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res. 2006;82:479-487.
27. Amrite AC, Edelhauser HF, Singh SR, Kompella UB. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol Vis. 2008; 14:150-160.
28. Amrite AC, Kompella UB. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J Pharm Pharmacol. 2005;57:1555-1563.
29. Vaezy S, Clark JI. Quantitative analysis of the microstructure of the human cornea and sclera using 2-D Fourier methods. J Microscopy. 1994;175:93-99.
30. Dawson DG, Ubels JL, Edelhauser HF. Cornea and sclera. In: Kaufman P, Ulm A, eds. Adler's Physiology of the Eye. 11th ed. New York: Elsevier. In press.
31. Olsen TW, Aabert SY, Geroski DH, Edelahauser HF. Human sclera: thickness and surface area. Am J Ophthalmol. 1998;125:237-241.
32. Pitkänen L, Ranta VP, Moilanen H, Urtti A. Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity. Invest Ophthalmol Vis Sci. 2005;46:641-646.
33. Cunha-Vaz J. The blood-ocular barriers. Surv Ophthalmol. 1979; 23:279-296.
34. Pitkänen L, Ranta VP, Moilanen H, Urtti A. Binding of betaxolol, metoprolol and oligonucleotides to synthetic and bovine ocular melanin, and prediction of drug binding to melanin in human choroidretinal pigment epithelium. Pharm Res. 2007;24:2063-2070.
35. Cheruvu NP, Kompella UB. Bovine and porcine transscleral solute transport: influence of lipophilicity and the choroid-Bruch's layer. Invest Ophthalmol Vis Sci. 2006;47:4513-4522.
36. Pitkänen L. Retinal Pigment Epithelium as a Barrier in Drug Permeation and as a Target of Non-Viral Gene Delivery. Kuopia, Finland: University of Kuopio and Kuopio University Hospital; 2007. PhD Thesis.
37. Amrite AC, Ayalasomayajula SP, Cheruvu NP, Kompella UB. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes- induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci. 2006;47:1149-1160.
38. DeVore DP, Eiferman RA, Keates EU, inventors. Collagenesis, Inc, assignee. Compound delivery using rapidly dissolving collagen film. U.S. patent 6,197,934. March 6, 2001.
39. Carvalho RAP, Murphree AL, Schmitt EE, inventors. Implantable and sealable system for unidirectional delivery of therapeutic agents to tissues. U.S. patent 7,195,774. March 27, 2007.
40. Pontes de Carvalho RA, Krausse ML, Murphree AL, Schmitt EE, Campochiaro PA, Maumenee IH. Delivery from episcleral exoplants. Invest Ophthalmol Vis Sci. 2006;47:4532-4539.
41. McAllister DV, Allen MG, Prausnitz MR. Microfabricated microneedles for gene and drug delivery. Annu Rev Biomed Eng. 2000;2:289-313.
42. Jiang J, Gill HS, Ghate D, et al. Coated microneedles for drug delivery to the eye. Invest Ophthalmol Vis Sci. 2007;48:4038-4043.
43. Jiang J, Moore JS, Edelhauser HF, Prausnitz MR. Instrsclera drug delivery to the eye using hollow microneedles. Pharm Res. 2009; 26:395-403.
44. Olsen TW, Feng X, Wabner K, et al. Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment. Am J Ophthalmol. 2006;142:777-787.
45. Jiang J, Moore JS, Edelhauser HF, Prausnitz MR. Intrascleral drug delivery to the eye using hollow microneedles. Pharm Res. 2009; 26:395-403.
46. Bejjani RA, Andrieu C, Bloquel C, et al. Electrically assisted ocular gene therapy. Surv Ophthalmol. 2007;52:196-208.
47. Bloquel C, Bejjani R, Bigey P, et al. Plasmid electrotransfer of eye ciliary muscle: principles and therapeutic efficacy using hTNFalpha soluble receptor in uveitis. FASEB J. 2006;20:389-391.
48. Touchard E, Bloquel C, Bigey P, et al. Effects of ciliary muscle plasmid electrotransfer of TNF-alpha soluble receptor variants in experimental uveitis. Gene Ther. 2009;16:862-873.
49. Maurice DM. Drug delivery to the posterior segment from drops. Surv Ophthalmol. 2002;47:S41-S52.
50. Loftsson T, Sigurdsson HH, Konradsdottir F, et al. Topical drug delivery to the posterior segment of the eye: anomatomical and physiological considerations. Pharmazie. 2008;63:171-179.
51. Takahashi K, Saishin Y, Saishin Y, et al. Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci. 2009;44: 409-415.
52. Doukas J, Mahesh S, Umeda N, et al. Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol. 2008;216:29-37.
53. Kiuchi K, Matsuoka M, Wu JC, et al. Mecamylamine suppresses basal and nicotine-stimulated choroidal neovascularization. Invest Ophthalmol Vis Sci. 2008;49:1705-1711.
54. Huang AJW, Tseng SCG, Kenyon KR. Paracellular permeability of corneal and conjunctival epithelia. Invest Ophthalmol Vis Sci. 1989;30:684-689.
55. Lux Biosciences. ClinicalTrials.org. NCT00851734. A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS). http://clinicaltrials.gov/ct2/show/NCT00851734. Accessed January 2, 2010.
56. Altinoǧlu EI, Russin TJ, Kaiser JM, et al. Near-infrared emitting fluorophore-doped calcium phosphate nanoparticles for in vivo imaging of human breast cancer. ACS Nano. 2008;28:2075-2084.
57. Heakal Y, Kester M. Nanoliposomal short-chain ceramide inhibits agonist-dependent translocation of neurotensin receptor 1 to structured membrane microdomains in breast cancer cells. Mol Cancer Res. 2009;7:724-734.
58. Kester M, Heakal Y, Fox T, et al. Calcium phosphate nanocomposite particles for in vitro imaging and encapsulated chemotherapeutic drug delivery to cancer cells. Nano Lett. 2008;8:4116-4121.
59. Kline CL, Shanmugavelandy SS, Kester M, Irby RB. Delivery of PAR-4 plasmid in vivo via nanoliposomes sensitizes colon tumor cells subcutaneously implanted into nude mice to 5-FU. Cancer Biol Ther. 2009;8:1831-1837.
60. Morgan TT, Muddana HS, Altinoglu EI, et al. Encapsulation of organic molecules in calcium phosphate nanocomposite particles for intracellular imaging and drug delivery. Nano Lett. 2008;8: 4108-4115.
61. Sun Y, Fox T, Adhikary G, et al. Inhibition of corneal inflammation by liposomal delivery of short-chain, C-6 ceramide. J Leukoc Biol. 2008;83:1512-1521.
62. Elijarrat-Binstock E, Domb AJ. A non-invasive ocular drug delivery. J Control Release. 2006;110:479-489.
63. EyeGate Pharma. Clintrials.org. NCT00765804. Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye. Phase II study. http://clinicaltrials.gov/ct2/show/NCT00765804. Accessed January 2, 2010.
64. Ciolino JB, Hoare TR, Iwata NG, et al. A drug-eluting contact lens. Invest Ophthalmol Vis Sci. 2009;50:3346-3352.
65. Miller DJ, Li SK, Tuitupou AL, et al. Passive and oxymetazolineenhanced delivery with a lens device: pharmacokinetics and efficacy studies with rabbits. J Ocul Pharmacol Ther. 2008;24:385-391.
66. Tso MOM, Shih CY, McLean IW. Is there a blood-brain barrier at the optic nerve head? Arch Ophthalmol. 1975;93:815-825.
67. Hofman P, Hoyng P, vanderWerf F, et al. Lack of blood-brain barrier properties in microvessels of the prelaminar optic nerve head. Invest Ophthalmol Vis Sci. 2001;42:895-901.
68. Birol G, Wang S, Budzynski E, et al. Oxygen distribution and consumption in the macaque retina. Am J Physiol Heart Circ Physiol. 2007;283:H1696-H1704.
69. Hayreh SS. Posterior ciliary artery circulation in health and disease: The Weisenfeld lecture. Invest Ophthalmol Vis Sci. 2004;45:749-757.
70. Williamson TH, Harris A. Ocular blood flow measurement. Br J Ophthalmol. 1994;78:939-945.
71. Campbell M, Nguyen AT, Kiang AS, et al. An experimental platform for systemic drug delivery to the retina. Proc Natl Acad Sci. 2009;106:17817-17822.
72. Rohrer B, Long Q, Coughlin B, et al. A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009;50:3056-3064.
73. Holers VM. The spectrum of complement alternative pathwaymediated diseases. Immunol Rev. 2008;223:300-316.
74. Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol. 2006;176:1305-1310.
75. Thurman JM, Renner B, Kunchithapautham K, et al. Oxidative stress renders retinal pigment epithelial cells susceptible to complement- mediated injury. J Biol Chem. 2009;284:16939-16947.
76. Csaky KG, Richman EA, Ferris FL 3rd. Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci. 2008;49:479-489.
77. Sunness JS, Applegate CA, Bressler NM, Hawkins BS. Designing clinical trials for age-related geographic atrophy of the macula: enrollment data from the geographic atrophy natural history study. Retina. 2007;27(2):204-210.
78. Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA, and SCORE Study Investigator Group. SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion. Ophthalmology. 2009;116(3): 504-512.